Linker-free PROTACs efficiently induce the degradation of oncoproteins

Jianchao Zhang, Congli Chen, Xiao Chen, Kefan Liao, Fengming Li, Xiaoxiao Song, Chaowei Liu, Ming-Yuan Su, Huiyong Sun, Tingjun Hou, Chris Soon Heng Tan, Lijing Fang, Hai RaoNature Communications 2025 · DOI

TL;DR

Researchers have challenged the long-standing dogma that a flexible linker is essential for PROTAC (Proteolysis-Targeting Chimera) design. By directly coupling single amino acid "degrons" to protein ligands, they created "linker-free" degraders that are smaller, more potent, and—crucially—orally bioavailable, outperforming their traditional linker-bearing counterparts in both cell and animal models.

What Problem Does This Paper Address?

Targeted Protein Degradation (TPD) is a revolutionary therapeutic approach that uses small molecules to hijack the cell's waste-disposal system (the ubiquitin-proteasome system) to destroy disease-causing proteins.

The most common TPD tools are PROTACs, which are heterobifunctional molecules: one end grabs the target protein, the other grabs an E3 ubiquitin ligase, and a linker connects them. However, these linkers are a major headache. They add significant molecular weight, often violating "drug-like" rules (Lipinski’s Rule of Five), and optimizing their length and composition is a tedious trial-and-error process. While "molecular glues" are smaller and more drug-like, they are notoriously difficult to design rationally. This paper asks: Can we build modular, rational degraders like PROTACs, but without the bulky linker?

Methods

The authors leveraged AATacs (Amino Acid-based Targeted chimeras), which use single N-terminal amino acids as degradation signals (N-degrons).

  • Design Strategy: They directly conjugated N-degrons (specifically Proline, Glycine, or Arginine) to ligands for two major oncoproteins: EML4-ALK (found in lung cancer) and BCR-ABL (found in leukemia).
  • Validation: They compared these "linker-free" versions (e.g., Pro-BA) against versions containing standard PEG (polyethylene glycol) linkers.
  • Mechanistic Studies: The team used Isothermal Titration Calorimetry (ITC) and NanoBRET to measure how well these molecules induced the formation of a "ternary complex" (Target-Degrader-E3 Ligase) inside living cells.
  • In Vivo Testing: They evaluated the pharmacokinetic (PK) profile and anti-tumor efficacy of the lead compound, Pro-BA, in xenograft mouse models using both intraperitoneal and oral administration.

Datasets

The study relied on several biological models and proteomic datasets:

  • Cell Lines: H3122 (NSCLC), K562 (CML), BaF3-EML4-ALK, and SK-N-BE(2) (neuroblastoma).
  • Quantitative Proteomics: A global proteome analysis of H3122 cells treated with Pro-BA was conducted to assess the degrader's selectivity across thousands of proteins.
  • Animal Models: H3122 xenograft nude mice were used for efficacy and PK/PD studies.

Key Insights and Ideas

  • The Linker is Not Mandatory: Contrary to the "integral part" status linkers have held in PROTAC design, the authors show that for certain E3 ligases (like the CTLH complex via its GID4 subunit), the linker can be entirely removed without losing function.
  • Less is More: The linker-free Pro-BA was significantly more potent ($DC_{50}$ of 74 nM) than its linker-bearing counterpart ($DC_{50}$ of 416 nM). It also showed better water solubility and cell permeability.
  • Stronger Cooperativity: Mechanistically, the linker-free design actually promoted a stronger interaction between the target protein and the E3 ligase. By removing the flexible spacer, the molecule may be forcing a more productive and stable orientation for ubiquitination.
  • Selectivity: Quantitative proteomics revealed that Pro-BA is highly selective, primarily targeting EML4-ALK and a few downstream targets like RRM2, with minimal off-target effects.

Key Results

  • Potency: Pro-BA induced an 82% reduction of EML4-ALK at 500 nM.
  • Oral Bioavailability: Pro-BA demonstrated a favorable PK profile with 35% oral bioavailability, a significant milestone for degraders which are often restricted to injection due to their size.
  • Tumor Inhibition: In mouse models, oral administration of Pro-BA (25 mg/kg) significantly shrank tumors and suppressed growth, showing better efficacy than the FDA-approved inhibitor Brigatinib.
  • Broad Applicability: The strategy translated to another target, BCR-ABL. The linker-free Pro-DA achieved a $DC_{50}$ of 8 nM, whereas the version with even a single PEG unit was ineffective.

Limitations and Future Work

While the results are promising, the authors acknowledge some boundaries:

  • E3 Ligase Specificity: This study focused on N-degrons recognized by the CTLH/GID4 and UBR family ligases. It remains to be seen if this "linker-free" paradigm applies to the most commonly used PROTAC ligases, CRBN and VHL.
  • Ligand Orientation: The success of a linker-free approach likely depends heavily on where the degron is attached to the ligand. If the attachment point is buried deep within the target protein's binding pocket, a linker may still be necessary to "reach" the E3 ligase.
  • Future Directions: The authors suggest that this design paradigm could lead to a new generation of "mini-PROTACs" that combine the rational design of chimeras with the favorable drug-like properties of molecular glues.

Summary updated

Abstract

Proteolysis-targeting chimeras (PROTACs) present a potentially effective strategy against various diseases via selective proteolysis. How to increase the efficacy of PROTACs remains challenging. Here, we explore the necessity of the linker, which has been deemed as an integral part of heterobifunctional PROTACs. Adopting single amino acid-based degradation signals, we find that the linker is not a required feature of the PROTACs. Notably, the linker-free PROTAC, Pro-BA, exhibits superior efficacy over its linker-bearing counterparts in degrading EML4-ALK and inhibiting lung cancer cell growth, as Pro-BA induces a stronger interaction between the target and the E3 ubiquitin ligase. Pro-BA is a water-soluble, orally administered degrader that significantly inhibits the tumor growth in a xenograft mouse model. The broad applicability of this linker-free PROTAC strategy is further validated through the development of BCR-ABL degrader. Our study introduces a design paradigm for PROTACs, potentially facilitating the advancement of more efficient therapeutic degraders.
BibTeX
@inproceedings{zhang2025linker,
  author = {Jianchao Zhang and Congli Chen and Xiao Chen and Kefan Liao and Fengming Li and Xiaoxiao Song and Chaowei Liu and Ming-Yuan Su and Huiyong Sun and Tingjun Hou and Chris Soon Heng Tan and Lijing Fang and Hai Rao},
  title = {{Linker-free PROTACs efficiently induce the degradation of oncoproteins}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-60107-7},
}
Figure